Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dexamethasone + prochlorperazine is a combination antiemetic regimen used to control nausea and vomiting, particularly in patients receiving chemotherapy. Clinical trials have shown that while granisetron is more effective than this combination for moderately emetogenic chemotherapy, the addition of dexamethasone to prochlorperazine significantly improves patients' experience during chemotherapy. Dexamethasone is a corticosteroid that works by binding to the glucocorticoid receptor, inhibiting pro-inflammatory signals and promoting anti-inflammatory signals. Prochlorperazine is a phenothiazine derivative that acts by blocking dopamine receptors in the brain, specifically targeting the chemoreceptor trigger zone and vomiting center.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dexamethasone + prochlorperazine.